Xenetic Biosciences
XBIO
12 hedge funds and large institutions have $1.22M invested in Xenetic Biosciences in 2021 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
98% more capital invested
Capital invested by funds: $615K → $1.22M (+$602K)
20% more funds holding
Funds holding: 10 → 12 (+2)
0.29% more ownership
Funds ownership: 0.35% → 0.64% (+0.29%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$242K |
| 2 |
Renaissance Technologies
New York
|
+$213K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$134K |
| 4 |
SPIA
Steward Partners Investment Advisory
New York
|
+$65.8K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$47.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$65K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $548K | +$213K | +8,095 | +48% |
|
|
2
Citadel Advisors
Miami,
Florida
| $201K | +$242K | +9,200 | New |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $198K | +$134K | +5,101 | +128% |
|
|
VF
4
Virtu Financial
New York
| $81K | +$46.3K | +1,760 | +90% |
|
|
5
Geode Capital Management
Boston,
Massachusetts
| $68K | +$47.6K | +1,808 | +137% |
|
6
Royal Bank of Canada
Toronto,
Ontario, Canada
| $59K | – | – | – |
|
|
SPIA
7
Steward Partners Investment Advisory
New York
| $54.5K | +$65.8K | +2,500 | New |
|
8
Morgan Stanley
New York
| $5K | +$5.26K | +200 | +769% |
|
9
UBS Group
Zurich,
Switzerland
| $2K | +$2.55K | +97 | New |
|
|
RE
10
RBC Europe
London,
United Kingdom
| $231 | – | – | – |
|
|
TSS
11
Two Sigma Securities
New York
| – | -$65K | -3,201 | Closed |
|
12
Wells Fargo
San Francisco,
California
| – | +$53 | +2 | +50% |
|
XBIO Hedge Fund Activity: Q1 2021 in Review
12 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q1 2021, worth a combined $1.22M — up 98% from $615K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new XBIO positions and 1 closed out — a net gain of 2 holders — while 6 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $242K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $65K sold.
- 12 institutional investors held Xenetic Biosciences (XBIO) as of Q1 2021, up from 10 in Q4 2020.
- Funds reported $1.22M of Xenetic Biosciences stock for Q1 2021, up 98% quarter-over-quarter.
- 3 funds opened new Xenetic Biosciences positions in Q1 2021 and 1 closed out, a net change of +2 holders.
- The largest Xenetic Biosciences buyer in Q1 2021 was Citadel Advisors, an estimated $242K added.
- The largest Xenetic Biosciences seller in Q1 2021 was Two Sigma Securities, an estimated $65K sold.
Based on aggregated 13F filings for Q1 2021.